Nasdaq has suspended trading in Chiasma (CHMA -1.5%) pending the release of news, in this case related to the FDA decision on its refiled marketing application seeking approval of Mycapssa (octreotide) for acromegaly. The agency’s action date is today.
The company received a CRL in April 2016 in response to its first submission citing the need for an additional clinical trial. It dutifully conducted a new study, OPTIMAL, that met the primary endpoint, announcing the positive outcome in July 2019.
https://seekingalpha.com/news/3586589-chiasma-shares-halted-pending-news-on-u-s-mycapssa-application
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.